Intravenous Product Packaging Market

Executive Summary

Intravenous Product Packaging Market was valued at US $115.21 billion in 2021 and is projected to grow at 15.33% CAGR over the forecast period to reach US $271.11 billion by 2027. Intravenous Product Packaging Market represented US $28.59 billion opportunity over 2019-2021 and estimated to create US $155.90 billion opportunity in 2027 over 2021.

Intravenous Product Packaging from Consainsights analyses the Intravenous Product Packaging Market in the Life Sciences industry over the forecast period to 2027.

Intravenous Product Packaging research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Intravenous Product Packaging segmentation includes Product, End User, Region and Geography.

Based on the Product, the Intravenous Product Packaging analysis covers IV BAGS, CANNULAS, OTHERS.

In Product segment, IV BAGS segment has highest cagr growth of 13.52%.

Based on the End User, the Intravenous Product Packaging analysis covers HOSPITALS, CLINICS, OTHERS.

In End User segment, HOSPITALS segment has highest cagr growth of 13.52%.

Based on the Region, the Intravenous Product Packaging analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 13.52%.

Based on the region, the Intravenous Product Packaging analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include BAXTER INC., NIPRO PVT. LTD., RENOLIT GROUP, SIPPEX MEDIPPEX GROUP, WIPAK GROUP, AMCOR LTD, B. BRAUN MEDICALS, DUPONT, MRK HEALTHCARE, NEOTEC MEDICAL INDUSTRIES and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, IV BAGS segment has the highest revenue of US $41.51 billion and is expected to grow at CAGR of 13.52% by 2027 IV BAGS segment has highest cagr growth of 13.52%.

IV BAGS

IV BAGS segment was valued at US $31.21 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $97.67 billion by 2027. IV BAGS segment represented US $10.30 billion opportunity over 2019-2021 and estimated to create US $56.16 billion opportunity in 2027 over 2021.

CANNULAS

CANNULAS segment was valued at US $25.30 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $79.19 billion by 2027. CANNULAS segment represented US $8.35 billion opportunity over 2019-2021 and estimated to create US $45.54 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $30.11 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $94.25 billion by 2027. OTHERS segment represented US $9.94 billion opportunity over 2019-2021 and estimated to create US $54.20 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $52.60 billion and is expected to grow at CAGR of 13.52% by 2027 HOSPITALS segment has highest cagr growth of 13.52%.

HOSPITALS

HOSPITALS segment was valued at US $39.55 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $123.77 billion by 2027. HOSPITALS segment represented US $13.05 billion opportunity over 2019-2021 and estimated to create US $71.17 billion opportunity in 2027 over 2021.

CLINICS

CLINICS segment was valued at US $21.49 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $67.25 billion by 2027. CLINICS segment represented US $7.09 billion opportunity over 2019-2021 and estimated to create US $38.67 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $25.59 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $80.09 billion by 2027. OTHERS segment represented US $8.45 billion opportunity over 2019-2021 and estimated to create US $46.06 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $71.16 billion and is expected to grow at CAGR of 13.52% by 2027 EUROPE segment has highest cagr growth of 13.52%.

EUROPE

EUROPE segment was valued at US $53.50 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $167.46 billion by 2027. EUROPE segment represented US $17.66 billion opportunity over 2019-2021 and estimated to create US $96.29 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $19.41 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $60.76 billion by 2027. ASIA-PACIFIC segment represented US $6.41 billion opportunity over 2019-2021 and estimated to create US $34.94 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $13.70 billion in 2019 and is projected to grow at 13.52% CAGR over the forecast period to reach US $42.89 billion by 2027. LAMEA segment represented US $4.52 billion opportunity over 2019-2021 and estimated to create US $24.66 billion opportunity in 2027 over 2021.